2 completed, 1 terminated. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Eating Disorders: new trials by email Literature Review of Eating Disorders trials Research Report on Eating Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral Naltrexone In Pediatric Eating Disorders Naltrexone Hydrochloride, Control - Anorexia Nervosa/Bulimia, Anorexia in Adolescence | Phase 2 / Phase 3 | Terminated | Rosemary Claire Roden | 9 | 2022-04-22 | 2025-08-19 |
| Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa Romosozumab Prefilled Syringe, Placebo, Zoledronic acid 5 mg - Bone Density, Low, Bone Loss | Phase 3 | Completed | Karen Klahr Miller, MD | 30 | 2021-09-20 | 2025-12-16 |
| Efficacy and Safety of Rimonabant on Weight Loss and Frequency of Binge Episodes in Obese Patients rimonabant (SR141716) - Obesity, Eating Disorders | Phase 3 | Completed | Sanofi | 289 | 2004-08-01 | 2009-04-07 |
Feeding and Eating Disorders (3) · Anorexia Nervosa (2) · Bulimia (2) · Bone Diseases, Metabolic (1) · Bulimia Nervosa (1) · Impulsive Behavior (1) · Obesity (1)
Mental Disorders (3) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Signs and Symptoms, Digestive (3) · Hyperphagia (2) · Nutritional and Metabolic Diseases (2) · Behavior (1) · Body Weight (1) · Bone Diseases (1) · Metabolic Diseases (1) · Musculoskeletal Diseases (1) · Nutrition Disorders (1) · Overnutrition (1) · Overweight (1)
Naltrexone (1) · Rimonabant (1) · Zoledronic Acid (1)
Karen Klahr Miller, MD (1) · Rosemary Claire Roden (1) · Sanofi (1)
United States (3) · Finland (1) · France (1) · Netherlands (1) · Portugal (1) · Sweden (1) · Switzerland (1)